Gene therapy applied to longevity aims to modify the expression of key aging genes (telomerase, follistatin, Klotho, APOE) via viral vectors. Animal data are promising, but the distance to human applications remains considerable: vector immunogenicity, genomic integration risks, and a lack of controlled clinical trials.
The BioViva story illustrates this tension. In November 2015, Elizabeth Parrish, CEO of BioViva Sciences, traveled to Colombia to receive two intravenous injections containing viral vectors carrying modified human genes. One targeted telomerase. The other, follistatin. No ethics committee had approved the procedure. BioViva announced via press release that Parrish's leukocyte telomeres had lengthened by 20 years within months. The scientific community met these claims with pronounced, and justified, skepticism.
Gene therapy: fundamental mechanisms
Gene therapy consists of introducing, modifying, or replacing genetic material in an organism's cells to correct a dysfunction or confer a new function. The principle is straightforward. The execution is not.
The most widely used delivery vehicle is the AAV (adeno-associated virus) vector. AAVs are harmless viruses whose genetic content has been emptied to insert the desired gene. Different types of AAV (called serotypes) have distinct tissue affinities: AAV8 preferentially targets the liver, AAV9 crosses the barrier between blood and brain, AAV1 efficiently reaches skeletal muscle (PubMed).
AAVs offer a major advantage: they rarely integrate into the host cell's own DNA. The inserted gene remains alongside the genome as an episome (a self-contained DNA fragment inside the nucleus), which reduces the risk of insertional mutagenesis (the accidental insertion of the gene into a wrong location in the genome). But this characteristic also means that the effect of the inserted gene dilutes over time in tissues that renew rapidly.
The other revolutionary tool is CRISPR-Cas9. Rather than adding an exogenous gene, CRISPR allows direct modification of the existing DNA sequence. In vivo editing — performed directly in the organism rather than on extracted cells — remains a major technical challenge, particularly in terms of specificity (off-target edits) and delivery to the right tissues.
The packaging capacity of AAVs constitutes a structural limitation. An AAV genome can hold only approximately 4.7 kilobases of genetic material. This is sufficient for relatively short genes like follistatin or telomerase, but excludes larger genes without complex splitting strategies.
Follistatin: the myostatin antagonist
Follistatin (FST) is a protein naturally produced by the body that blocks the action of several brakes on muscle growth, particularly myostatin and activins. By neutralizing these factors, follistatin lifts a powerful biological brake on muscle growth (PubMed).
Myostatin is the most powerful known negative regulator of skeletal muscle mass. The MSTN gene encodes this protein, and its loss of function produces spectacular phenotypes. The most documented human example is a German child identified in 2004 by Markus Schuelke's team. Carrying a double mutation that inactivated the MSTN gene (both copies were non-functional), he displayed extraordinarily developed musculature at birth. At age 4, he could hold 3 kg dumbbells at arm's length (PubMed).
In animals, myostatin loss-of-function cases are well characterized. Belgian Blue cattle, selectively bred for decades for a natural MSTN gene mutation, display massive muscular hypertrophy (the "double-muscling" phenotype). MSTN knockout mice develop skeletal muscle mass two to three times greater than normal mice.
Myostatin-deficient mice develop skeletal muscle mass two to three times greater than normal, demonstrating the powerful braking role of this protein on muscle growth.
The relevance to longevity is direct. Sarcopenia — the progressive loss of muscle mass and function with age — is an independent mortality factor in older adults. Maintaining muscle mass is one of the most robust levers for preserving mobility, metabolism, and functional autonomy. By neutralizing myostatin, follistatin represents a theoretical lever to counter this decline.
From muscular dystrophies to clinical trials
The first serious clinical application of follistatin gene therapy targeted muscular dystrophies, not aging. In 2015, Jerry Mendell's team at Nationwide Children's Hospital published results from a phase I/IIa trial in six patients with Becker muscular dystrophy. An AAV1 vector carrying the FS344 gene (a follistatin isoform) was injected directly into the quadriceps muscle (PubMed).
Results were encouraging. The six-minute walk test showed improvement in four of six patients. No serious adverse events were reported over two years of follow-up. But the trial had no placebo group, the sample size was tiny, and the injection was local, not systemic. Extrapolating these results to a systemic anti-aging application requires several logical leaps that the data do not yet support.
Bryan Johnson and follistatin
In 2024, Bryan Johnson — tech entrepreneur turned media figure in the fight against aging through his Blueprint program — announced he had received an AAV vector carrying the follistatin gene. His stated objective: increase muscle mass and slow age-related sarcopenia.
Johnson reported strength and muscle mass gains in the following months. He shared biometric data on his platforms, including DEXA measurements and physical performance tests.
The problem is methodological. Bryan Johnson simultaneously follows dozens of interventions (optimized nutrition, structured exercise, intensive supplementation, constant medical monitoring). Isolating the effect of follistatin gene therapy in this context is impossible. There is no control group. The data have not been published in a peer-reviewed journal. Placebo effect and confirmation bias are obvious confounders.
This case illustrates a recurring phenomenon in the longevity field: wealthy individuals serve as voluntary guinea pigs for experimental therapies, generate media attention, but produce no data usable by the scientific community.
Beyond follistatin: other genetic targets for longevity
Telomerase (hTERT): Maria Blasco's work
Telomeres are protective caps at the ends of chromosomes, comparable to the plastic tips on shoelaces. They shorten with each cell division, and this shortening is considered one of the biological clocks of aging. Telomerase (hTERT) is the enzyme capable of restoring telomere length, but its activity is normally switched off in most adult cells.
In 2012, Maria Blasco's team at the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid demonstrated that a single injection of AAV9 carrying the TERT gene in adult (one year) and old (two year) mice extended their median lifespan by 24% and 13% respectively, without increasing tumor incidence (PubMed).
This was a remarkable result. The primary concern with telomerase is its link to cancer — cancer cells massively reactivate telomerase to divide indefinitely. That transient AAV-mediated activation did not increase cancer rates in these mice was reassuring, but does not close the debate for humans.
Subsequent work by the same team showed that AAV-TERT gene therapy improved glucose tolerance, osteoporosis, neuromuscular coordination, and several aging biomarkers in mice. But ten years after this publication, no human clinical trial has been initiated for this approach. The distance between mouse and human remains the bottleneck.
Klotho: cognition and longevity
The klotho protein, identified in 1997 by Makoto Kuro-o, takes its name from the Greek Fate who spins destiny's thread. Klotho-deficient mice develop an accelerated aging syndrome (vascular calcification, osteoporosis, skin atrophy, reduced lifespan). Conversely, klotho overexpression extends lifespan by 20 to 30% in mice (PubMed).
In 2023, Dena Dubal's team at UCSF published results in Nature showing that a single systemic injection of secreted klotho improved cognitive function in aged mice and rhesus macaques. Hippocampal synaptic plasticity was restored, and performance on spatial memory tests improved significantly (PubMed).
Gene therapy approaches (AAV vector carrying the klotho gene) are being explored in parallel, with the advantage of prolonged expression compared to a single protein injection. Preclinical data are promising, but no clinical trial is underway for an aging-related indication.
APOE: rewriting genetic risk
The APOE gene exists in three main variants: APOE2, APOE3, and APOE4. The APOE4 variant is the most powerful known genetic risk factor for Alzheimer's disease (risk multiplied by 3 to 12 depending on copy number) and is associated with increased cardiovascular risk. Conversely, APOE2 is protective (PubMed).
The idea of converting APOE4 to APOE2 through genome editing (CRISPR) is one of the most ambitious applications of gene therapy for longevity. The two variants differ by only two amino acids. Technically, the modification is minimal. Practically, it requires editing the gene in billions of hepatic and cerebral cells with absolute precision.
Preclinical work in mice has demonstrated the feasibility of in vivo conversion using base editors (a CRISPR variant that modifies a single DNA letter without cutting the double strand). But editing rates remain insufficient for a clinically significant effect, and the risk of off-target edits in an organ as critical as the brain imposes an extremely high safety bar.
BioViva and self-experimentation
Returning to Elizabeth Parrish. Her 2015 self-injection combined two transgenes: hTERT (telomerase) and follistatin, delivered via AAV vectors. BioViva claimed via press release that Parrish's leukocyte telomere length had increased from 6.71 kb to 7.33 kb in six months, representing a "rejuvenation" of twenty years by their interpretation.
Several problems render these claims unverifiable. Quantitative PCR measurement of telomere length has significant technical variability. A single subject without a control group permits no conclusions. The data have never been published in a peer-reviewed journal. And leukocyte telomere length is a contested biomarker of biological aging — its correlation with actual longevity is weak and inconsistent.
Parrish subsequently founded BioViva Sciences in the Bahamas, then worked with clinics in Colombia and Honduras to offer experimental gene therapies. The company has still published no controlled clinical trial.
AAV vectors: power and limitations
AAV vectors are the workhorses of modern gene therapy. Several AAV therapies have received marketing authorization for rare genetic diseases: Luxturna (RPE65, hereditary blindness), Zolgensma (SMN1, spinal muscular atrophy), Hemgenix (factor IX, hemophilia B).
These clinical successes validate the technology platform. But they concern severe monogenic diseases where the benefit-risk ratio justifies residual uncertainties. Aging is a multigenic, multifactorial process, and the targeted individuals are presumably healthy. The benefit-risk calculation is fundamentally different.
AAV limitations are well documented. Immunogenicity (the vector's ability to trigger an immune reaction) is the primary problem. Between 30 and 60% of the adult population already has antibodies capable of neutralizing common AAV types, rendering the therapy ineffective in these individuals (PubMed). After a first AAV injection, the immune system develops a robust response that prevents any re-administration of the same serotype. There is therefore only one "shot" per serotype.
Hepatic inflammatory response is another risk. In 2020, three children treated with a high dose of AAV8 in a clinical trial for X-linked myotubular myopathy died of acute liver failure. The event led to a reassessment of doses and monitoring protocols.
Limited packaging capacity (4.7 kb) excludes large genes. And transgene expression, while prolonged in post-mitotic tissues such as muscle or liver, is not permanent in rapidly renewing tissues.
CRISPR and in vivo editing: state of the art
CRISPR represents the next frontier. Rather than adding an exogenous gene via a vector, CRISPR enables permanent modification of the endogenous genome. For longevity applications, this would open the possibility of definitive corrections — converting APOE4 to APOE2, activating telomerase in a controlled manner, or inactivating pro-aging genes.
The 2023 approval of Casgevy for sickle cell disease and beta-thalassemia (two hereditary hemoglobin disorders) marked a historic turning point for clinical CRISPR. But this therapy works ex vivo: blood stem cells are extracted from the patient, edited in the laboratory, then reinfused.
In vivo editing — directly within the organism — is considerably more complex. Delivering CRISPR to the right tissues, with sufficient efficiency and acceptable specificity, remains a challenge. Lipid nanoparticles (LNPs), the tiny fat capsules used successfully for Covid-19 mRNA vaccines, are being explored as delivery vehicles for CRISPR. Intellia Therapeutics demonstrated in 2021 that a single LNP-CRISPR injection targeting the TTR gene in the liver reduced transthyretin levels by 87% in patients with hereditary amyloidosis (PubMed).
For longevity, in vivo CRISPR applications are at the preclinical stage. Base editors (which modify a single DNA letter without cutting the double strand) and prime editors (which can rewrite short sequences with even greater precision) offer greater accuracy than classical CRISPR, but their in vivo efficiency remains to be optimized.
Risks and unknowns
Gene therapy for longevity compounds the uncertainties inherent to gene therapy with those specific to intervening on aging.
Insertional mutagenesis (the accidental integration of the inserted gene into a location in the genome where it could activate a cancer gene or disable a protective one) is a low but non-zero risk with AAVs. Very long-term safety data (decades) in humans do not yet exist, because approved AAV therapies are recent.
The immune response, beyond initial immunogenicity, raises the question of autoimmunity. Prolonged expression of a transgenic protein could theoretically trigger an immune response against the transduced cells themselves.
Irreversibility is perhaps the most fundamental problem. Once a gene is inserted or modified, there is no simple method to "undo" the intervention if adverse effects appear years later. For a therapy administered to healthy individuals with a preventive objective, this irreversibility demands a standard of evidence far higher than that required for life-threatening diseases.
Ethics and medical tourism
The absence of approved anti-aging gene therapies by regulatory agencies has not prevented their commercialization. Clinics in Honduras, Colombia, the Bahamas, and other loosely regulated jurisdictions offer AAV injections carrying follistatin, telomerase, or other transgenes to wealthy clients.
Prices range from $25,000 to over $500,000. Protocols are not standardized. Post-injection follow-up varies. Safety data are not systematically collected. Clients sign liability waivers.
This gene therapy medical tourism reproduces a pattern already seen with stem cells: a promising but premature technology, commercialized before science has established its efficacy and safety, in permissive regulatory environments, to a wealthy and motivated clientele.
The question of unequal access also arises. If anti-aging gene therapies prove effective, their initial cost will reserve them for the wealthiest. Biological aging could become, even more than it already is, a matter of financial means.
Outlook: toward approved gene therapies for aging
The field is progressing. Gene delivery tools are improving (new AAV serotypes, LNPs, non-viral vectors). Genome editing precision is increasing (prime editing, base editors). Understanding of the molecular mechanisms of aging is becoming more refined.
But the distance between animal data and human clinical evidence remains the limiting factor. No gene therapy is in a phase III clinical trial for an aging-related indication in 2026. Existing trials target specific muscular diseases or rare genetic conditions. Extrapolation to normal aging will require long-duration trials, with large cohorts and validated endpoints.
The FDA and EMA do not recognize aging as a therapeutic indication. This seemingly technical regulatory point constitutes a structural obstacle. Without a recognized indication, no pivotal clinical trial. Without a pivotal trial, no marketing authorization.
The most likely scenario is that the first approved "anti-aging" gene therapies will enter through the door of age-related diseases — severe sarcopenia, macular degeneration, heart failure — before seeing their indication broadened. The path will be long. The shortcuts taken by offshore clinics do not make it shorter. They make it more dangerous.
Frequently asked questions
References
-
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341-355 (PubMed).
-
Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98(16):9306-9311 (PubMed).
-
Schuelke M, Wagner KR, Stolz LE et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682-2688 (PubMed).
-
Mendell JR, Sahenk Z, Malik V et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23(1):192-201 (PubMed).
-
Bernardes de Jesus B, Vera E, Schneeberger K et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med. 2012;4(8):691-704 (PubMed).
-
Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309(5742):1829-1833 (PubMed).
-
Castner SA, Gupta S, Wang D et al. Longevity factor klotho enhances cognition in aged nonhuman primates. Nat Aging. 2023;3(8):931-937 (PubMed).
-
Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106-118 (PubMed).
-
Boutin S, Monteilhet V, Veron P et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population. Hum Gene Ther. 2010;21(6):704-712 (PubMed).
-
Gillmore JD, Gane E, Taubel J et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493-502 (PubMed).
